Abstracts tagged "Activity score and systemic lupus erythematosus (SLE)"

Abstract Number: 941 • 2012 ACR/ARHP Annual Meeting
Validity and Reliability of the Systemic Lupus Activity Questionnaire (SLAQ): A Prospective Study
Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Traditional assessments of systemic lupus erythematosus (SLE) disease activity, such as the SLE Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus Activity Measure…
Abstract Number: 610 • 2012 ACR/ARHP Annual Meeting
B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation
Eoghan M. McCarthy¹, Ruth Lee¹, Joan Ni Gabhann², Siobhan Smith², Michele Doran³, Gaye Cunnane³, Donough G. Howard¹, Paul G. O'Connell⁴, Grainne M. Kearns⁵ and Caroline Jefferies², ¹Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ²Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³Dept of Rheumatology, St. James Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ⁵Rheumatology Department, Beaumont Hospital, Dublin, Ireland
Background/Purpose: B Lymphocyte Stimulator(BLyS) plays an important role in the pathogenesis of Systemic Lupus Erythematosus(SLE). Whilst trials of anti BLyS-targeted therapy have shown promise, the optimal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].